Sweden's Mentice Q4 net sales rise 5.3% on increase in order intake

Mentice AB

26/02/2026 06:19

Overview

Sweden simulation solutions provider's Q4 net sales rose 5.3% despite currency headwinds

Q4 EBITDA increased to 23.0 MSEK, driven by solid order intake

Company's Q4 net income reached 13.0 MSEK, up from 2.0 MSEK last year

Outlook

Company did not provide specific guidance for future quarters or full-year 2026

Result Drivers

ORDER INTAKE - Co reported a significant increase in order intake, with organic growth of 25.3%, despite currency headwinds

SALES GROWTH - Net sales rose 5.3% in Q4, driven by organic growth of 17.6%, offset by 12.3% currency impact

MARKET ACTIVITY - CEO cited increased market activity in MedTech sector and strategic initiatives as growth drivers

Company press release: ID:nMFN3TdSzZ

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 90.80 mln
Q4 EPS
SEK 0.46
Q4 Net Income
SEK 13 mln
Q4 Cash Flow From Operating Activities
SEK 1.50 mln
Q4 EBITDA
SEK 23 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Mentice AB is SEK39.89, about 185% above its February 25 closing price of SEK14.00

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)